Introduction and Objective: People with diabetes (PWD) who are beneficiaries of Medicaid have worse glycemic outcomes than those with private insurance and are at increased risk for poor clinical outcomes. Barriers to accessing automated insulin delivery (AID) systems include age, complex/extensive prior authorization policies, unclear documentation requirements, and healthcare provider implicit bias about who is an appropriate candidate for AID. The current study analyzed glycemic outcomes of Medicaid beneficiaries using the MM780G system.Methods: De-identified real-world data from United States MiniMed™ 780G (MM780G) users (N=7,632) receiving Medicaid and who had ≥10 days of Carelink™ data uploaded between January 2023 and October 2025 were analyzed. Glycemic outcomes and insulin delivered were assessed in the overall group and in a cohort (N=1,825) using recommended optimal settings (ROS: 100mg/dL glucose target with an active insulin time [AIT] of 2hrs).Results: Self-reported type of diabetes was 68.7% with T1D, 17.5% with T2D, and 13.8% unreported/other. Glycemic outcomes and insulin delivered were assessed (Table). Most (>70%) of the insulin was delivered by the system for both groups.Conclusion: Medicaid beneficiaries with diabetes using MiniMed™ 780G ROS met ADA-recommended glycemic targets. Reducing the barriers to AID system access may improve their glycemic control, as many are at increased risk for poor clinical outcomes.
J. McVean: Employee; Current; Medtronic. M. Liu: Employee; Current; Medtronic. C. Rodriguez: Employee; Current; Medtronic. K.V. Tran: Employee; Current; Medtronic. J.J. Shin: Employee; Current; Medtronic. R. Vigersky: Employee; Current; Medtronic.
Source link
Leave a Reply